We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

034020:KRXDoosan Enerbility Co., Ltd. Analysis

Data as of 2026-06-03 - not real-time

₩100,000.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Doosan Enerbility is trading near a key support level of roughly 99,700 KRW with a forward price‑to‑earnings multiple close to 100, far above the industry average of about 30, signaling a potentially overvalued market price. Technical signals are mixed: the 20‑day SMA sits above the 50‑day SMA, suggesting a longer‑term bullish bias, yet the price remains below both averages, the MACD histogram is negative, and volume is on a downtrend, indicating short‑term weakness. The RSI around 37 points to a near‑oversold condition, which could set the stage for a modest bounce if buying pressure returns. On the fundamentals side, revenue is growing at a healthy 13‑plus percent, but margins are thin, free cash flow is modest, and debt‑to‑equity exceeds 50, raising concerns about financial flexibility.
The market sentiment is extremely bullish, reflected by a fear‑greed index in the “Extreme Greed” zone, but this optimism may be overstretched given the high valuation and volatile price action. With an upside potential of roughly 38% to the median analyst target, the stock could benefit from its expanding renewable‑energy portfolio, yet investors should weigh the high beta, 58% 30‑day volatility, and sizable drawdown risk before committing.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hovering at technical support
  • RSI near oversold levels
  • Bearish MACD histogram and declining volume

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Revenue growth and expanding clean‑energy portfolio
  • Upside potential of ~38% to analyst median target
  • Long‑term bullish SMA alignment despite short‑term weakness

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • High forward P/E relative to peers
  • Elevated debt load and thin profitability
  • Regulatory and geopolitical exposure across multiple regions

Key Metrics & Analysis

Financial Health

Revenue Growth13.70%
Profit Margin0.88%
P/E Ratio99.7
ROE2.37%
ROA1.80%
Debt/Equity56.51
Op. Cash Flow₩758.3B
Free Cash Flow₩119.4B
Industry P/E30.1

Technical Analysis

TrendBullish
RSI37.1
Support₩99,700.00
Resistance₩139,200.00
MA 20₩115,030.00
MA 50₩110,220.00
MA 200₩87,424.50
MACDBearish
VolumeDecreasing
Fear & Greed Index92.75

Valuation

Target Price₩138,884.47
Upside/Downside38.88%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta1.20
Volatility58.09%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.